ReNeuron Group Plc (LON:RENE)’s stock price crossed below its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $207.08 and traded as low as $167.00. ReNeuron Group shares last traded at $167.00, with a volume of 50,250 shares traded.

The stock has a 50-day simple moving average of GBX 206.40 and a two-hundred day simple moving average of GBX 224.52. The firm has a market cap of $53.16 million and a PE ratio of -3.69.

ReNeuron Group (LON:RENE) last issued its earnings results on Thursday, July 11th. The company reported GBX (45.20) (($0.59)) earnings per share for the quarter, topping the Zacks’ consensus estimate of GBX (49.80) (($0.65)) by GBX 4.60 ($0.06). Equities research analysts forecast that ReNeuron Group Plc will post -78.4799994 EPS for the current fiscal year.

About ReNeuron Group (LON:RENE)

ReNeuron Group plc develops and sells cell-based therapies in the United Kingdom. The company's lead therapeutic candidate is CTX stem cell therapy, which has been completed Phase II clinical trial for the treatment of patients living with chronic disability following stroke, as well as that has been completed Phase I clinical trial to treat limb ischaemia.

Recommended Story: How does inflation affect different investments?

Receive News & Ratings for ReNeuron Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ReNeuron Group and related companies with MarketBeat.com's FREE daily email newsletter.